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Prognostication in malignant pleural effusion: one size does not fit all 
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Physicians are poor at predicting survival in patients with malignant pleural effusion (MPE). This is exemplified by the 
TIME 2 trial 1 where, despite criteria precluding trial entry with an estimated survival of <3 months, 34% of 
participants died within 90 days. An added complexity is the variation in exercise capacity associated with how 
effectively the pleural effusion is controlled. The resulting impact a large, undrained effusion has on performance 
status renders this a poor prognostic indicator. Accurate estimates of prognosis are important to inform discussion 
with patients and guide management and follow-up strategies. This is of particular significance given the short 
survival conferred by a diagnosis of MPE, with median survival figures between  3 – 12 months 2.   
Until now, two prognostic scores have been reported for use in MPE. The LENT score 3, (combining pleural fluid 
lactate dehydrogenase (LDH), Eastern Cooperative Oncology Group performance status (ECOG PS), neutrophil: 
lymphocyte ratio and tumour type) externally validated in 10 studies, categorises patients into low, moderate and 
high risk groups (median survival 319 days, 130 days and 44 days respectively)3. The PROMISE score 4 combines 
biological (TIMP1 pleural fluid biomarker) and clinical parameters (chemotherapy, radiotherapy, haemoglobin, 
leucocyte count, C-reactive protein (CRP), ECOG PS and cancer type) to give four risk categories: Group A (lowest 
risk; <25% 90 day mortality) to D (highest risk; ≥75% 90 day mortality)4. A variation of the LENT score (modified 
LENT) has also been developed in patients with MPE secondary to adenocarcinoma 5.   
In a recent publication in Respirology, Quek et al 6 report their evaluation of the LENT, modified LENT and clinical 
PROMISE scores in an Asian MPE population and report a new score: the SELECT model. Patients were identified 
from a pleuroscopy database, with data available to calculate LENT and modified-LENT scores in 130 participants and 
clinical PROMISE score in 57. C-statistics demonstrated that no score was strong at survival prognostication in their 
patient population. In response, the SELECT model was developed using data from 147 patients in the database. 
Incorporating readily accessible variables (sex, ECOG PS, leukocyte count, epidermal growth factor receptor (EGFR) 
mutation, chemotherapy and primary tumour type) patients were stratified into low risk (predicted probability of 90 
day mortality ≤10%) and high risk (predicted probability of 90 day mortality >10%) groups. Comparison of the four 
prognostic scores using logistic regression in 52 patients demonstrated the SELECT model performed better than the 
LENT and PROMISE scores, but not in comparison to modified-LENT. The authors conclude the SELECT score is 
accurate at identifying patients with a high probability of survival at 90 days.  
The authors address a relevant limitation of the LENT and PROMISE scores; newer targeted cancer therapies confer a 
survival advantage not accounted for in these prognostic models. With wider access to tyrosine kinase inhibitors for 
EGFR positive mutations, the LENT and PROMISE scores risk underestimating survival in patients with 
adenocarcinoma. By incorporating EGFR status, the SELECT prognostic model may now provide a more accurate 
survival estimate for patients with MPE. Although previous studies have sought to address this issue 5, SELECT is the 
first prognostic score developed to date from a patient population with different primary cancer types to include 
EGFR status. 
However, external prospective validation in an unselected cohort is essential before the SELECT model is utilized in 
clinical practice. In contrast to the LENT and PROMISE scores (developed and validated prospectively in ‘all comers’ 
with MPE), a significant limitation of the study from Quek et al. is the retrospective design and single-centre 
evaluation. Patients with a greater level of dependency were under-represented in the authors’ analysis of 
participants undergoing pleuroscopy; 81% of whom had an ECOG status of 0 or 1. Higher risk categories were 
represented with similarly low numbers; 10 of 130 participants were ‘high risk’ by LENT criteria and 0 of 57 by 
PROMISE Group D. Dividing participants into two prognostic groups, the SELECT model may help to distinguish those 
with a low 90 day mortality, but the real-world utility of a ‘high risk’ classification (>10% 90 day mortality risk) has yet 
to be determined.  
 
Notably, the rate of EGFR positive mutation among patients with lung adenocarcinoma in the Asian population 
studied by Quek et al. was approximately four times that of the UK, Australian and Netherlands based LENT 
population (56% in the Asian cohort vs 12-15% respectively)3. This reflects the findings of previous studies 7, 8, which 
observe geographical variation in the incidence of EGFR mutation, with highest rates seen in the Asian-Pacific 
subgroups. Quek et al. highlight how inter-population differences can limit the transferability of a prognostic tool 
validated in one MPE cohort to another. The authors demonstrate the heterogeneity of the MPE population and 
subsequently, the importance of understanding local trends.   
How should we therefore approach the next patient with a new MPE diagnosis? Survival estimates from prognostic 
scores are useful to inform discussion and provide some guidance about life expectancy. No model is perfect 
however and as therapeutic options advance, prognostic scores require adaptation and re-validation to keep up. It is 
essential to understand the limitations of whichever score is used, considered also in the context of the local 
population. No score yet offers a survival estimate accurate enough to determine an individualized treatment 
strategy. Factors such as patient preference and symptom burden should be regarded in equal measure. As our 
understanding of the complexity of the condition deepens, a universal ‘one-size-fits-all’ approach to patients with 
MPE is rendered an outdated concept.  
 
Dr Alexandra Dipper, MBChB, MRCP 
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